US 12,173,329 B2
Acyl-ACP reductase with improved properties
Mathew Rude, San Diego, CA (US); Na Trinh, Burlingame, CA (US); Andreas Schirmer, San Diego, CA (US); and Jacob Gano, San Diego, CA (US)
Assigned to Genomatica, Inc., San Diego, CA (US)
Filed by Genomatica, Inc., San Diego, CA (US)
Filed on Jul. 20, 2023, as Appl. No. 18/355,990.
Application 17/405,685 is a division of application No. 16/272,303, filed on Feb. 11, 2019, granted, now 11,130,944, issued on Sep. 28, 2021.
Application 18/355,990 is a continuation of application No. 17/405,685, filed on Aug. 18, 2021, abandoned.
Application 16/272,303 is a continuation of application No. 15/222,657, filed on Jul. 28, 2016, granted, now 10,208,294, issued on Feb. 19, 2019.
Application 15/222,657 is a continuation of application No. 14/761,299, granted, now 9,683,219, issued on Jun. 20, 2017, previously published as PCT/US2014/011859, filed on Jan. 16, 2014.
Claims priority of provisional application 61/753,273, filed on Jan. 16, 2013.
Prior Publication US 2024/0117324 A1, Apr. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/02 (2006.01); C12P 7/04 (2006.01); C12P 7/24 (2006.01); C12P 7/6409 (2022.01)
CPC C12N 9/0008 (2013.01) [C12P 7/04 (2013.01); C12P 7/24 (2013.01); C12P 7/6409 (2013.01); C12Y 102/0108 (2013.01)] 20 Claims
 
1. A variant acyl-ACP reductase (AAR) polypeptide comprising at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 81, wherein said variant AAR polypeptide comprises one or more mutations at an amino acid position corresponding to position 8, 10, 11, 16, 17, 18, 19, 21, 22, 23, 24, 31, 34, 38, 43, 50, 58, 63, 64, 65, 83, 86, 96, 112, 113, 116, 117, 118, 120, 135, 148, 150, 153, 154, 155, 157, 159, 168, 172, 177, 179, 180, 187, 188, 191, 209, 210, 211, 236, 238, 253, 274, 277, 281, 282, 283, 284, 285, 286, 291, 316, 324, 328, 335, and 337 of SEQ ID NO: 81, and wherein said variant AAR polypeptide catalyzes the conversion of an acyl-ACP to a fatty aldehyde.